# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Chardan Capital analyst Brian Dobson initiates coverage on NOVONIX (NASDAQ:NVX) with a Buy rating and announces Price Target...
As previously announced, NOVONIX has agreed to divest MD South Tenements Pty Ltd, its wholly owned subsidiary that holds the Mo...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...
U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday.